 Todd Bull
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 42 | 2023 | 1737 | 4.160 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 96 | 1.800 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 183 | 1.360 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 218 | 1.320 |
Why?
| | Vena Cava Filters | 2 | 2020 | 50 | 0.860 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 117 | 0.810 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 61 | 0.730 |
Why?
| | Airway Obstruction | 1 | 2021 | 168 | 0.670 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 233 | 0.640 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 190 | 0.640 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 240 | 0.620 |
Why?
| | Thrombosis | 4 | 2023 | 297 | 0.620 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 744 | 0.600 |
Why?
| | Epoprostenol | 4 | 2012 | 133 | 0.570 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 33 | 0.560 |
Why?
| | Vascular Resistance | 5 | 2021 | 338 | 0.550 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 928 | 0.540 |
Why?
| | Endovascular Procedures | 1 | 2020 | 268 | 0.540 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 138 | 0.530 |
Why?
| | Antihypertensive Agents | 2 | 2012 | 429 | 0.520 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 122 | 0.510 |
Why?
| | Exercise Test | 3 | 2023 | 545 | 0.500 |
Why?
| | Altitude Sickness | 1 | 2017 | 172 | 0.490 |
Why?
| | Pulmonary Artery | 9 | 2023 | 1028 | 0.480 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 733 | 0.470 |
Why?
| | Echocardiography | 2 | 2020 | 555 | 0.470 |
Why?
| | Vasodilator Agents | 4 | 2023 | 305 | 0.460 |
Why?
| | Humans | 65 | 2023 | 114925 | 0.460 |
Why?
| | Perioperative Care | 1 | 2014 | 126 | 0.430 |
Why?
| | Altitude | 1 | 2017 | 433 | 0.420 |
Why?
| | Anticoagulants | 5 | 2023 | 547 | 0.420 |
Why?
| | Hypoxia | 5 | 2023 | 960 | 0.410 |
Why?
| | Endothelial Cells | 5 | 2011 | 685 | 0.410 |
Why?
| | Sulfones | 1 | 2012 | 97 | 0.390 |
Why?
| | Blood Cells | 1 | 2010 | 38 | 0.360 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 231 | 0.360 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 61 | 0.350 |
Why?
| | Hypertension, Portal | 2 | 2020 | 61 | 0.340 |
Why?
| | Piperazines | 1 | 2012 | 313 | 0.340 |
Why?
| | Oxygen Consumption | 1 | 2012 | 588 | 0.330 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 63 | 0.330 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 283 | 0.330 |
Why?
| | Blood Coagulation | 2 | 2021 | 217 | 0.320 |
Why?
| | Virus Diseases | 1 | 2011 | 196 | 0.320 |
Why?
| | Lung | 8 | 2022 | 3593 | 0.300 |
Why?
| | Time Factors | 2 | 2017 | 6125 | 0.290 |
Why?
| | Acute Lung Injury | 1 | 2010 | 300 | 0.280 |
Why?
| | Blood Vessels | 1 | 2008 | 180 | 0.270 |
Why?
| | Middle Aged | 18 | 2022 | 26801 | 0.270 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 524 | 0.260 |
Why?
| | Male | 25 | 2022 | 55655 | 0.260 |
Why?
| | Ventricular Function, Right | 4 | 2023 | 252 | 0.260 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 8 | 0.260 |
Why?
| | Microarray Analysis | 1 | 2005 | 119 | 0.250 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 535 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2007 | 417 | 0.240 |
Why?
| | Female | 24 | 2022 | 59571 | 0.240 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 280 | 0.230 |
Why?
| | Heart Ventricles | 4 | 2023 | 711 | 0.230 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.220 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1523 | 0.210 |
Why?
| | Heparin | 2 | 2021 | 222 | 0.200 |
Why?
| | Biopsy | 1 | 2005 | 1045 | 0.200 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 15 | 0.200 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 16 | 0.190 |
Why?
| | Embolectomy | 1 | 2020 | 11 | 0.180 |
Why?
| | Aromatase | 1 | 2020 | 30 | 0.180 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.180 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 476 | 0.180 |
Why?
| | Thrombectomy | 1 | 2020 | 52 | 0.180 |
Why?
| | Tuberculosis | 1 | 2003 | 241 | 0.180 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 408 | 0.180 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 24 | 0.170 |
Why?
| | Drug Resistance | 1 | 2020 | 158 | 0.170 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 132 | 0.170 |
Why?
| | Risk Factors | 7 | 2018 | 8637 | 0.170 |
Why?
| | Endothelium, Vascular | 5 | 2007 | 848 | 0.170 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 225 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2023 | 408 | 0.160 |
Why?
| | Critical Illness | 2 | 2021 | 643 | 0.160 |
Why?
| | Aged | 10 | 2021 | 19120 | 0.160 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 995 | 0.160 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 57 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 291 | 0.150 |
Why?
| | Estrogens | 1 | 2020 | 312 | 0.150 |
Why?
| | Hemodynamics | 2 | 2014 | 1014 | 0.150 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 63 | 0.150 |
Why?
| | Acute Disease | 1 | 2020 | 915 | 0.150 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 19 | 0.140 |
Why?
| | Schistosoma | 1 | 2017 | 18 | 0.140 |
Why?
| | Purines | 2 | 2023 | 159 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.140 |
Why?
| | Risk Assessment | 3 | 2023 | 2975 | 0.140 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 449 | 0.140 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 96 | 0.140 |
Why?
| | Adult | 14 | 2023 | 30604 | 0.140 |
Why?
| | Pandemics | 2 | 2021 | 1325 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2023 | 12543 | 0.130 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 39 | 0.130 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 267 | 0.130 |
Why?
| | Intensive Care Units | 1 | 2020 | 619 | 0.130 |
Why?
| | Patient Care Team | 1 | 2020 | 516 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 934 | 0.130 |
Why?
| | Cohort Studies | 3 | 2017 | 4903 | 0.130 |
Why?
| | Systole | 1 | 2016 | 171 | 0.130 |
Why?
| | Prognosis | 3 | 2013 | 3344 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 334 | 0.120 |
Why?
| | Health Surveys | 1 | 2017 | 443 | 0.120 |
Why?
| | Blood Pressure | 2 | 2016 | 1537 | 0.120 |
Why?
| | Myocardial Contraction | 1 | 2016 | 312 | 0.120 |
Why?
| | Heart Failure | 2 | 2020 | 1952 | 0.120 |
Why?
| | ROC Curve | 1 | 2016 | 448 | 0.120 |
Why?
| | Exercise | 3 | 2022 | 1641 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 81 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 515 | 0.120 |
Why?
| | Anesthetics | 1 | 2014 | 54 | 0.110 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 485 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 68 | 0.110 |
Why?
| | Precision Medicine | 1 | 2017 | 339 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2021 | 4427 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1400 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 496 | 0.110 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.100 |
Why?
| | Respiratory System Agents | 1 | 2013 | 22 | 0.100 |
Why?
| | Phenotype | 3 | 2010 | 2817 | 0.100 |
Why?
| | Drug Storage | 1 | 2012 | 59 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2010 | 2769 | 0.100 |
Why?
| | Drug Stability | 1 | 2012 | 151 | 0.100 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.100 |
Why?
| | Drug Approval | 1 | 2012 | 78 | 0.100 |
Why?
| | Case-Control Studies | 4 | 2020 | 3008 | 0.100 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 10 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3053 | 0.100 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 27 | 0.100 |
Why?
| | Europe | 1 | 2012 | 336 | 0.100 |
Why?
| | Troponin | 1 | 2011 | 44 | 0.100 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 73 | 0.100 |
Why?
| | Antithrombins | 1 | 2011 | 49 | 0.100 |
Why?
| | Hyponatremia | 1 | 2011 | 37 | 0.100 |
Why?
| | Ultrasonography | 2 | 2011 | 633 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 64 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 114 | 0.090 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 25 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2021 | 9105 | 0.090 |
Why?
| | Registries | 3 | 2022 | 1760 | 0.090 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 1801 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2011 | 295 | 0.090 |
Why?
| | Demography | 1 | 2010 | 262 | 0.090 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 296 | 0.080 |
Why?
| | Prospective Studies | 4 | 2022 | 6218 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2222 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2010 | 460 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 56 | 0.080 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 112 | 0.080 |
Why?
| | United States | 4 | 2022 | 12209 | 0.080 |
Why?
| | Electrocardiography | 1 | 2011 | 562 | 0.080 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 34 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 119 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 929 | 0.080 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 105 | 0.080 |
Why?
| | Research Design | 1 | 2013 | 932 | 0.080 |
Why?
| | Animals | 9 | 2017 | 31837 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 396 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 238 | 0.070 |
Why?
| | Colorado | 1 | 2017 | 4089 | 0.070 |
Why?
| | Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1220 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2010 | 1087 | 0.070 |
Why?
| | Quality of Life | 3 | 2022 | 2359 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1440 | 0.070 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 141 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 797 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2005 | 57 | 0.060 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 24 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1458 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 21 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 108 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 82 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 3897 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 966 | 0.060 |
Why?
| | Adolescent | 4 | 2021 | 17826 | 0.060 |
Why?
| | Biomarkers | 4 | 2013 | 3418 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2008 | 676 | 0.060 |
Why?
| | Algorithms | 1 | 2011 | 1474 | 0.060 |
Why?
| | Carrier Proteins | 1 | 2008 | 696 | 0.060 |
Why?
| | Vasodilation | 3 | 2010 | 416 | 0.060 |
Why?
| | Apoptosis | 3 | 2008 | 2371 | 0.060 |
Why?
| | Cattle | 2 | 2017 | 924 | 0.060 |
Why?
| | Blood Circulation | 1 | 2003 | 34 | 0.060 |
Why?
| | CD36 Antigens | 1 | 2003 | 37 | 0.060 |
Why?
| | Forecasting | 1 | 2005 | 333 | 0.060 |
Why?
| | E-Selectin | 1 | 2003 | 53 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 530 | 0.060 |
Why?
| | Blood Donors | 1 | 2004 | 89 | 0.050 |
Why?
| | Veins | 1 | 2003 | 56 | 0.050 |
Why?
| | Blood | 1 | 2003 | 96 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 3549 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 277 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 374 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 954 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 151 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 49 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 50 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 111 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 230 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 51 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4406 | 0.050 |
Why?
| | Rivaroxaban | 1 | 2023 | 211 | 0.050 |
Why?
| | Proteomics | 2 | 2022 | 844 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2023 | 153 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 198 | 0.050 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1133 | 0.050 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.050 |
Why?
| | Brachial Artery | 2 | 1999 | 176 | 0.050 |
Why?
| | Catheters | 1 | 2021 | 65 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2003 | 425 | 0.050 |
Why?
| | Mass Screening | 1 | 2007 | 1011 | 0.050 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 57 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 227 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 103 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 135 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 227 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 328 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1391 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 121 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1635 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2324 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 184 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1080 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 618 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1644 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 295 | 0.040 |
Why?
| | Antigens, Ly | 1 | 2017 | 45 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 180 | 0.040 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 93 | 0.040 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 48 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2021 | 668 | 0.030 |
Why?
| | Education | 1 | 2017 | 95 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 679 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 154 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 4524 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2199 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 225 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 1754 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 504 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 447 | 0.030 |
Why?
| | Mice | 2 | 2007 | 14935 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 777 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2326 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 671 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2020 | 706 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1893 | 0.030 |
Why?
| | Perioperative Period | 1 | 2012 | 49 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2013 | 122 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 6363 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 23 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 172 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 51 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 115 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2485 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 218 | 0.020 |
Why?
| | Introns | 1 | 2011 | 227 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 117 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 246 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 162 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 136 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 220 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 245 | 0.020 |
Why?
| | Leg | 1 | 2011 | 225 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 236 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2558 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 28 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 353 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 38 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 612 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1176 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 167 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 154 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 4718 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10476 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 1897 | 0.020 |
Why?
| | Research | 1 | 2009 | 395 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1317 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2010 | 827 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1422 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 344 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1372 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 305 | 0.010 |
Why?
| | Mutation | 2 | 2005 | 3353 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1530 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 89 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 78 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2392 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 61 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3248 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2132 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 345 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 103 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 1953 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 350 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 281 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 388 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 4634 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 729 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 5525 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 6 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2002 | 499 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 13 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 21 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 51 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 142 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 184 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 154 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 82 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 741 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 387 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 244 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 947 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1998 | 1663 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 523 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|